Home > Journals > Minerva Biotechnology and Biomolecular Research > Past Issues > Minerva Biotecnologica 2017 December;29(4) > Minerva Biotecnologica 2017 December;29(4):200-6

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW  STEM CELL-BASED BIOTECHNOLOGICAL ADVANCES IN REGENERATIVE MEDICINE 

Minerva Biotecnologica 2017 December;29(4):200-6

DOI: 10.23736/S1120-4826.17.02357-6

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Preclinical studies on stem cells as a prelude to clinical application: animal models or alternatives?

Sharmila FAGOONEE

Institute for Biostructures and Bioimages (CNR), Molecular Biotechnology Center, Turin, Italy


PDF


Stem cells offer an unequalled opportunity for the therapy of a wide array of human acute and chronic diseases for which no efficient surgical or pharmacological treatments exist. Stem cells are considered a valid alternative in human disease modeling and drug testing. However, when cell therapy is considered, stem cells have to be functionally studied, not only in vitro, in silico and ex vivo, but also on the organism as a whole as a prelude to its clinical application. There are a large number of diseases for which stem cell therapies have been studied in animal models, and have provided outputs applicable to human clinical trials. Mostly rodents are used for proof-of-principle studies, but larger animals may provide the ultimate validation, by accurately addressing potential risks and benefits of cell-based therapy before translation to the clinic. In this review, we discuss the pros and cons of the use of animal models for stem cell research and the much-sought after alternatives for this mission of the 21st century.


KEY WORDS: Stem cells - Regenerative medicine - Models, animal

top of page